Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i2.10
32 pages

Liposomal Formulations of Cyclosporin A: A Biophysical Approach to Pharmacokinetics and Pharmacodynamics

A. Fahr
Department of Pharmaceutical Technology and Biopharmacy, University of Marburg, Ketzerbach 63, 35032 Marburg, Germany
J. Seelig
Department of Biophysical Chemistry, Biocenter of the University of Basel, Klin-gelbergstrabe 70, CH-4056 Basel, Switzerland

RESUMO

There are about 20 publications about liposomal formulations of Cyclosporin A (CyA) in the pharmaceutical and preclinical literature. Liposomal formulations were developed in order to reduce the nephrotoxicity of CyA and to increase pharmacological effects. However, conflicting results have been published as to the therapeutic properties of these formulations. This is also true for the change in pharmacokinetics and organ distribution of the liposomally encapsulated CyA as compared to conventionally formulated CyA. Using biophysical methods, it could be shown that CyA is not tightly entrapped in liposomal membranes, despite its high lipophilicity. CyA shows retardation only at high lipid concentrations in blood, following a massive injection of liposomes.This effect may diminish nephrotoxicity, as could be demonstrated by in vitro studies using a model tubule system. The results of these studies can be used to predict the formulation behavior in vivo and to optimize liposomal formulations. When applied in an early phase of the drug formulation process, these types of biophysical experiments can also help minimize animal experiments. However, these basic interaction studies cannot cover all physiological, pharmacological, and toxic effects in animals and humans.


Articles with similar content:

In Vitro Experimental Studies and Numerical Modeling to Investigate the Biomechanical Effects of Surgical Interventions on the Spine
Critical Reviews™ in Biomedical Engineering, Vol.47, 2019, issue 4
Cesare Faldini, Maria Luisa Ruspi, Luca Cristofolini, Mohammadreza Chehrassan
Sponges as Toxicological Bioassay Test Organisms
Hydrobiological Journal, Vol.38, 2002, issue 6
D. I. Stom, A. E. Balayan
ADVANCED TURBULENCE MODELLING OF WINGTIP VORTICES
TSFP DIGITAL LIBRARY ONLINE, Vol.5, 2007, issue
Karthikeyan Duraisamy, Alistair Revell, Gianluca Iaccarino
Boolean Modeling in Quantitative Systems Pharmacology: Challenges and Opportunities
Critical Reviews™ in Biomedical Engineering, Vol.47, 2019, issue 6
Matthew Putnins, Ioannis P. Androulakis
Current Nanotechnological Strategies for Treating Glaucoma
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 5
Goutam Rath, Tarun Garg, Amit Kumar Goyal, Gagandeep Goyal